Single Protein in Liver Cells Both Repairs Damage and Blocks Scarring

Liver disease affects hundreds of millions globally, and one of its most challenging aspects is that the same cells responsible for healing — hepatic stellate cells (HSCs) — also drive fibrosis, or scarring, when chronically activated. Finding a single molecular target that can tip HSCs toward repair and away from scarring has been a major goal of hepatology research.

This study, published in Hepatology, used mouse models of both acute and chronic liver injury induced by carbon tetrachloride (CCl4) to compare HSC gene expression across injury states. By analyzing RNA sequencing data from primary HSCs and publicly available single-cell RNA-seq datasets, the researchers identified Lhx2, a transcription factor, as a key regulator of HSC dual functionality. Notably, Lhx2 expression was significantly higher in healthy liver tissue compared to fibrotic liver in both mouse and human samples.

Functional experiments showed that knocking down Lhx2 impaired liver recovery and reduced cell proliferation after acute injury. Conversely, HSC-specific Lhx2 overexpression accelerated hepatocyte proliferation and reduced fibrosis after chronic injury. Mechanistically, Lhx2 suppressed activated HSC behaviors — including fibrogenesis, proliferation, and migration — by upregulating SMAD6, which blocks the pro-fibrotic TGF-β signaling pathway. Lhx2 also acted as an upstream regulator of hepatocyte growth factor (HGF), a critical mediator of liver regeneration.

These findings position Lhx2 as a rare dual-function therapeutic target: one that simultaneously promotes tissue repair and prevents pathological scarring. This is clinically significant because most current antifibrotic strategies do not also support regeneration.

Caveats include that the study is primarily preclinical, relying on mouse models and human dataset analysis. Translation to human therapeutic interventions will require further validation in clinical settings.